Advertisement

Topics

AstraZeneca scores double approvals in Japan for asthma and ovarian cancer

06:15 EST 19 Jan 2018 | Pharmafile

AstraZeneca has unveiled a double dose of approvals awarded to its medicines in Japan: Fasenra (benralizumab) has been given authorisation as an add-on treatment for severe asthma sufferers, while Lynparza (olaparib) has been given the go-ahead as a maintenance therapy in patients with ovarian cancer who responded to chemotherapy, regardless of BRCA mutation status.

read more

Original Article: AstraZeneca scores double approvals in Japan for asthma and ovarian cancer

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca scores double approvals in Japan for asthma and ovarian cancer"

Quick Search
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...